Complement Activation and Induction of Interleukin-1 Production during Hemodialysis

Haeffner‐Cavaillon, Nicole; Fischer, Eddy; Bacle, F.; Carreno, Marie‐Paule; Maillet, F; Cavaillon, Jean Marc; Kazatchkine, M. D.

doi:10.1159/000415479

Cited by 32 publications

(18 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This could explain the results of Ghysen et al [9] where a rise in TNF was seen during cuprophane HD but not during polyacrylonitrile (PAN) HD, but is not con sistent with the data from Herbelin et al [3] where plasma TNF levels, though elevated, were no different in patients exposed to cu prophane or PAN and did not change in either group before and after a dialysis. There was also no influence of type of mem brane on the increased intramonocytic IL-1 activity reported by Haeffner-Cavaillon et al [19]. Though extracellular IL-1 was low in the HD patients regardless of the dialyser membrane used reported by Blumenstein et al [15], cell-associated IL-1 was increased in patients treated with cuprophane and PAN sheet membranes though the mechanism of activation may differ with the two mem branes.…”

Section: Discussionmentioning

confidence: 80%

Evaluation of the in vitro Production of Tumour Necrosis Factor by Monocytes in Dialysis Patients

Ryan

Beynon²,

Rees³

et al. 1991

Blood Purif

View full text Add to dashboard Cite

Modification of the cellular immune response in uraemia is partly responsible for the increased susceptibility to infection found in dialysis patients. In order to study this further we have evaluated the in vitro production of tumour necrosis factor (TNF) by peripheral-blood monocytes (PBMCs) to stimulation by lipopolysaccharide (LPS) from dialysis patients with end-stage renal failure. The patients were subdivided into two groups according to the type of dialysis: those undergoing haemodialysis (HD; n ≈ 12) and continuous ambulatory peritoneal dialysis (CAPD; n = 18). Results were compared with those of controls taken from healthy laboratory staff (n = 7). The experiments show that the secretion of TNF by PBMCs in response to LPS is significantly augmented in patients undergoing HD when compared to those on CAPD (81.3 ± 38.7 vs. 18.2 ± 13.3 U/ml, mean ± SD, p < 0.001) and controls (81.3 ± 38.7 vs. 18.1 ± 6.6 U/ml, p < 0.001). There was no significant difference between the CAPD group and controls. In vitro production of TNF fell slightly following a single HD session (81.3 ± 38.7 U/ml before HD and 50.5 ± 28.7 U/ml after HD, p < 0.05). We conclude from this study that TNF release from PBMCs is augmented in patients with chronic renal failure receiving chronic HD but not in a similar group receiving CAPD, in vitro. TNF release, however, is suppressed immediately following a single HD session. We suggest that HD rather than uraemia per se up-regulates monocyte secretion of TNF in vitro and that this is not an immediate response to activation by membrane polymer.

show abstract

Section: Discussionmentioning

confidence: 80%

Evaluation of the in vitro Production of Tumour Necrosis Factor by Monocytes in Dialysis Patients

Ryan

Beynon²,

Rees³

et al. 1991

Blood Purif

View full text Add to dashboard Cite

show abstract

“…Direct cell-membrane interaction in the dialyzer has been favoured as the pri mary mechanism [5,22]. In addition, bacterial pyrogen in the dialysate [23] and activated complement components [24,25] are also thought to be involved in the cell stimulat ing process. Hollow fibre dialyzers, particulary those containing ethylene oxide sterilized regenerated cellu lose, have been shown to contain water-extractable sub stances which may also serve as a stimulus for monocyte activation [26,27].…”

Section: Discussionmentioning

confidence: 99%

Monocyte Phenotype and Interleukin-1 Production in Patients Undergoing Haemodialysis

Schiller¹,

Ziegler‐Heitbrock

Meyer

et al. 1991

Nephron

View full text Add to dashboard Cite

The expression of MHC class II (HLA-DR) and complement receptor (CRl) surface molecules on CD 14 + monocytes were compared with the production of the monokine interleukin-1β (IL-1β) in patients with endstage renal disease undergoing maintenance haemodialysis (HD) with hollow fibre dialyzers containing cellulose (CE, n = 8) and polysulfone (PS, n = 7) membranes. Monocyte staining was performed in blood samples obtained at the beginning and after 3 h of HD. Analysis of surface marker expression was done by immunofluorescence staining and flow cytometry analysis. Specific fluorescence intensity for both CRl and class II (HLA-DR) antigens was increased in patients treated with CE membranes at the beginning of a dialysis treatment when compared to healthy control values. Interestingly, after 3 h on dialysis a further increase was noted for CRl complement receptor expression whereas the increased HLA-DR expression was no longer detectable. In contrast, specific fluorescence intensity for both antigens was not significantly different from controls, either before or after dialysis, in patients treated with PS. The capacity of peripheral blood mononuclear cells to produce IL-1β spontaneously in vitro in the two patient groups was found to parallel results on phenotypic expression of surface molecules. The present study demonstrates that functional signs of monocyte activation, as evidenced by an augmented IL-1β production, in some patients on long-term HD correlate with an increased expression of two functionally important monocyte surface marker molecules.

show abstract

“…It in duces polymorphonuclear leukocytes to re lease oxidative products and/or lysosomal enzymes [10]. C5a also promotes monocytes to produce interleukin-1 [16]. The leukocytedirected activities of C5a are retained even when its anaphylactic property has been abrogated by carboxypeptidase N.…”

Section: Activation Of Complement and Physiological Consequencesmentioning

confidence: 99%

Biomedical Polymers Differ in Their Capacity to Activate Complement

Janatova¹,

Cheung²,

Parker³

1991

Complement Inflamm

View full text Add to dashboard Cite

Conventionally, complement activation by biomedical polymers has been evaluated by determining the C3a concentration in the fluid phase only. According to this criterion, biomaterials such as hemodialysis membranes made from cellulosic or various synthetic polymers were classified as activators or nonactivators of complement. Since certain membranes bind large quantities of C3a from the fluid phase, classification based on fluid- phase C3a concentration has in some instances been inaccurate. As follows from the comparison of complement activation by cuprophane and polyacrylonitrile membranes, the capacity of a biomedical polymer to activate complement is not determined by the number of potential covalent binding sites on its surface. Biomaterial itself may lack hydroxyl and/or amino groups, and yet it may activate C3 in human serum very efficiently. Some of the biomaterials may also bind unactivated/unfragmented C3 whether in the absence or presence of other serum proteins. In addition, binding of factor B (a promotor of C3 activation) and binding of factor H (an inhibitor of C3 activation) to certain biomaterials have been found to be independent of complement activation and unaffected by the presence or absence of C3. Thus, it is becoming apparent that the requirements for the formation and stability of the C3 convertase on artificial surfaces differ from those on biological membranes, and that the relative magnitude of binding of factor B and factor H to the surface per se cannot be used as a reliable indicator of the capacity of the biomaterial to activate complement. Further studies are necessary to elucidate the molecular mechanisms of C3 and C5 activation on the surfaces of biomedical polymers. Its understanding should lead to the development of new or modification of existing artificial membranes which would cause less adverse effects for patients during extracorporeal procedures.

show abstract

Complement Activation and Induction of Interleukin-1 Production during Hemodialysis

Cited by 32 publications

References 0 publications

Evaluation of the in vitro Production of Tumour Necrosis Factor by Monocytes in Dialysis Patients

Evaluation of the in vitro Production of Tumour Necrosis Factor by Monocytes in Dialysis Patients

Monocyte Phenotype and Interleukin-1 Production in Patients Undergoing Haemodialysis

Biomedical Polymers Differ in Their Capacity to Activate Complement

Contact Info

Product

Resources

About